What is Lucigen?
Located in Middleton, Wis., Lucigen is dedicated to empowering life scientists by developing cutting-edge solutions for complex challenges in DNA cloning, amplification, protein expression, and next-generation sequencing. The company's product portfolio, which includes a diverse range of cloning kits, competent cells, and enzymes, is designed to streamline genomic research. Lucigen's focus on simplifying intricate molecular biology experiments enables researchers to achieve faster and more efficient results, positioning it as a key player in the advancement of genomic technologies.
How much funding has Lucigen raised?
Lucigen has raised a total of $3.9M across 2 funding rounds:
Private Equity
$1.7M
Angel/Seed
$2.2M
Private Equity (2012): $1.7M, investors not publicly disclosed
Angel/Seed (2014): $2.2M, investors not publicly disclosed
What's next for Lucigen?
The recent major strategic investment signals a pivotal phase for Lucigen, likely enabling the company to accelerate product development, expand its market reach, and enhance its service offerings. This infusion of capital is expected to fuel further innovation in molecular biology tools, potentially leading to breakthroughs in areas such as personalized medicine and advanced diagnostics. Lucigen's strategic positioning and continued focus on simplifying genomic research suggest a promising future for the company as it scales its operations and solidifies its market leadership.
See full Lucigen company page
